Menu Search
Equities

Quanterix Corp

QTRX:NMQ

Quanterix Corp

Actions
Health CareMedical Equipment and Services
  • Price (USD)11.72
  • Today's Change0.70 / 6.35%
  • Shares traded417.58k
  • 1 Year change-50.32%
  • Beta1.3041
Data delayed at least 15 minutes, as of Nov 21 2024 21:00 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 14-Dec-23
  • 19-Sep-24
  • 17-Oct-24
  • 14-Nov-24
Select bar for recommendation details.
Recommendations14-Nov-24
Buy1
Outperform4
Hold1
Sell0
Strong Sell0

Share price forecast in USD

The 7 analysts offering 12 month price targets for Quanterix Corp have a median target of 20.00, with a high estimate of 28.00 and a low estimate of 10.00. The median estimate represents a 70.65% increase from the last price of 11.72.
High138.9%28.00
Med70.6%20.00
Low-14.7%10.00

Earnings history & estimates in USD

On Aug 08, 2024, losses of -0.25 per share. This result was in line with the consensus of the 6 analysts following the company
The next earnings announcement is expected on Feb 26, 2025.
Average growth rate-15.83%
Quanterix Corp reported annual 2023 losses of -0.86 per share on Feb 29, 2024.
Average growth rate-4.27%
More ▼

Revenue history & estimates in USD

Quanterix Corporation had 3rd quarter 2024 revenues of 35.70m. This bettered the 34.17m consensus of the 6 analysts covering the company. This was 25.46% above the prior year's 3rd quarter results.
Average growth rate+3.35%
Quanterix Corporation had revenues for the full year 2023 of 122.37m. This was 15.96% above the prior year's results.
Average growth rate+22.91%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.